Business Context and Reporting Period
This Form 8-K is filed by Autonomix Medical, Inc. (AMIX) on July 9, 2026. The report addresses a specific regulatory event regarding the company's listing status on the Nasdaq Capital Market.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on compliance with Nasdaq listing rules.
Material Changes
The primary material change reported is the resolution of a listing deficiency:
- Previous Status: On January 14, 2026, the company received a deficiency letter from Nasdaq because its stock closed below the $1.00 minimum bid price requirement for 30 consecutive business days.
- Current Status: On July 9, 2026, Nasdaq notified the company that it has regained compliance. The stock closed at or above $1.00 per share for 10 consecutive business days (June 24, 2026, through July 8, 2026).
- Outcome: The matter regarding the Bid Price Rule deficiency is now closed.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operations, or discussion of new risks. The only risk addressed was the potential delisting due to low stock price, which has been resolved as of the report date.
Investor Verification Checklist
- Verify the current trading price of AMIX to ensure it remains above the $1.00 threshold.
- Confirm the company's continued compliance with other Nasdaq listing requirements (e.g., shareholder equity, market value of listed securities).
- Review recent 10-Q or 10-K filings for underlying financial performance that may influence future stock price stability.